Real Time Polymerase Chain Reaction for Hepatitis B Screening in Donor Corneas in the Central Eye Bank of Iran

Overview

Journal J Ophthalmic Vis Res

Specialty Ophthalmology

Date 2018 Nov 28

PMID 30479707

Authors

Shahram Samiee

Mozhgan Rezaei Kanavi

Mohammad Ali Javadi

Abouzar Bagheri

Sahar Balagholi

Marzieh Sadat Hashemi

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to report the results of the use of real-time polymerase chain reaction (PCR) for the diagnosis of hepatitis B virus (HBV) infection in cornea donors at the Central Eye Bank of Iran.

Methods: Between 2014 and 2016, all cornea donors that had negative screening serologic results for hepatitis B (HB) surface antigen, HB surface antibody (Ab), hepatitis C virus Ab, human immune deficiency virus Ab, human T-cell leukemia virus Ab, and syphilis, and positive serology for HB core Ab were subjected to real-time PCR with a detection limit of 400 IU/mL to identify HBV DNA. Positive results for HBV DNA were considered occult HBV infections in these donors.

Results: Over the 3-year period, 122 out of 10448 cornea donors had negative screening serologic tests outside of HB core Ab. Of which, 90 cases were subjected to real-time PCR. Occult HBV was detected in 11 cases (12.2%), resulting in the rejection of the corresponding corneas. The remaining 79 cases (87.8%) had negative results for HBV DNA and the corresponding corneas were used for transplantation.

Conclusion: Implementation of PCR for the detection of occult HBV in cornea donors is necessary to not only increase the security level of cornea donation but also minimize the rejection rate of donors that have isolated HB core Ab reactivity.

References

Nardone A, Anastassopoulou C, Theeten H, Kriz B, Davidkin I, Thierfelder W . A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect. 2008; 137(7):961-9. DOI: 10.1017/S0950268808001672. View

Nabil Ahmed Said Z . An overview of occult hepatitis B virus infection. World J Gastroenterol. 2011; 17(15):1927-38. PMC: 3082745. DOI: 10.3748/wjg.v17.i15.1927. View

Poorolajal J, Majdzadeh R . Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci. 2011; 14(4):249-58. PMC: 3129112. View

Ni Y, Huang L, Chang M, Yen C, Lu C, You S . Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology. 2007; 132(4):1287-93. DOI: 10.1053/j.gastro.2007.02.055. View

Solves P, Mirabet V, Alvarez M . Hepatitis B transmission by cell and tissue allografts: how safe is safe enough?. World J Gastroenterol. 2014; 20(23):7434-41. PMC: 4064088. DOI: 10.3748/wjg.v20.i23.7434. View

Ng E, Cheng P, Ng A, Hoang T, Lim W . Influenza A H5N1 detection. Emerg Infect Dis. 2005; 11(8):1303-5. PMC: 3320469. DOI: 10.3201/eid1108.041317. View

Fornes M, Jimenez M, Eisman M, Gomez Villagran J, Villalba R . Nucleic acid-amplification testing for hepatitis B in cornea donors. Cell Tissue Bank. 2015; 17(2):341-4. DOI: 10.1007/s10561-015-9539-0. View

Borderie V . Donor selection, retrieval and preparation of donor tissue. Donor selection. Dev Ophthalmol. 2009; 43:22-30. DOI: 10.1159/000223836. View

Dreier J, Kroger M, Diekmann J, Gotting C, Kleesiek K . Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med. 2004; 14(2):97-103. DOI: 10.1111/j.0958-7578.2004.0486.x. View

10.

Biswas R, Tabor E, Hsia C, Wright D, Laycock M, Fiebig E . Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion. 2003; 43(6):788-98. DOI: 10.1046/j.1537-2995.2003.00424.x. View

11.

Cabrerizo M, Bartolome J, Caramelo C, Barril G, Carreno V . Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology. 2000; 32(1):116-23. DOI: 10.1053/jhep.2000.8541. View

12.

Chemin I, Trepo C . Clinical impact of occult HBV infections. J Clin Virol. 2006; 34 Suppl 1:S15-21. DOI: 10.1016/s1386-6532(05)80005-8. View

13.

Candotti D, Allain J . Transfusion-transmitted hepatitis B virus infection. J Hepatol. 2009; 51(4):798-809. DOI: 10.1016/j.jhep.2009.05.020. View

14.

Allain J . Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 2004; 86(2):83-91. DOI: 10.1111/j.0042-9007.2004.00406.x. View

15.

Brojer E, Grabarczyk P, Liszewski G, Mikulska M, Allain J, Letowska M . Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology. 2006; 44(6):1666-74. DOI: 10.1002/hep.21413. View

16.

Hollinger F, Sood G . Occult hepatitis B virus infection: a covert operation. J Viral Hepat. 2009; 17(1):1-15. DOI: 10.1111/j.1365-2893.2009.01245.x. View

17.

Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H . Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood. 2002; 100(7):2637-41. DOI: 10.1182/blood-2002-03-0798. View

18.

Zaaijer H, Torres P, Ontanon A, Ponte L, Koppelman M, Lelie P . Multiple surface antigen mutations in five blood donors with occult hepatitis B virus infection. J Med Virol. 2008; 80(8):1344-9. DOI: 10.1002/jmv.21233. View

19.

Tazhibi M, Hajivandi A, Tafti A, Fallahzadeh H . The efficacy of hepatitis B vaccine in Iranian population: A systematic review and meta-analysis. J Educ Health Promot. 2014; 3:53. PMC: 4114169. DOI: 10.4103/2277-9531.134741. View

20.

Said Z, El Sayed M, Salama I, Aboel-Magd E, Mahmoud M, Setouhy M . Occult hepatitis B virus infection among Egyptian blood donors. World J Hepatol. 2013; 5(2):64-73. PMC: 3642725. DOI: 10.4254/wjh.v5.i2.64. View